Clinical trials: Diet, Reducing
Reduction of Dietary Fumonisin Bioavailability
G-PUR® for Reduced Dietary Fumonisin Bioavailability
This prospective, placebo-controlled, randomized, monocentric, double-blind, crossover study in healthy volunteers aims to assess the effect of a single dose of 2 g G-PUR® on bioavailability of dietary fumonisin and to evaluate…
- Trial name
- NCT04494178
- Testing
- 2.0g G-PUR®
- Where
- Austria
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Glock Health, Science and Research GmbH
Obesity
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female…
- Trial name
- NCT00747929
- Testing
- S-2367 800 mg, S-2367 1600 mg, Reduced Calorie Diet
- Where
- 38 sites in United States
- Volunteers
- 724 people, healthy volunteers welcome
- Sponsor
- Shionogi
Clostridium Difficile Infection Recurrence
Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections
The purpose of this study is to determine whether a single strain capsulated probiotic, when used after standard C. difficile antibiotic therapy, is effective in reducing the risk of infection recurrence mediated by a decrease in…
- Trial name
- NCT05606159
- Testing
- Bacillus velezensis DSM 33864
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novozymes A/S
Healthy
Evaluation of Nephure™, and the Reduction of Dietary Oxalate, in Healthy Volunteers
The purpose of this double-blind study is to determine the effect of reducing oxalates in the diet of healthy volunteers by using Nephure, an oxalate-reducing enzyme, as compared to placebo.
- Trial name
- NCT03661216
- Testing
- Nephure Oxalate-reducing Enzyme
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Captozyme, Inc.
Familial Hypercholesterolemia
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
The main purpose of this study is to describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab when added to standard of care in children 10 to 17 years of age with familial hypercholesterolemia.
- Trial name
- HAUSER-OLE (NCT02624869)
- Testing
- Evolocumab
- Where
- 46 sites in United States, Australia and 21 more
- Volunteers
- 163 people
- Sponsor
- Amgen
Smoking, Tobacco Use Disorder
A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers
A randomized, double-blind, active-controlled, crossover, pilot study to evaluate the safety and efficacy of CigRx™ Lozenge, a dietary supplement, in daily smokers in temporarily reducing the desire to smoke
- Trial name
- NCT01262170
- Testing
- CigRx Lozenge, Tobacco Lozenge
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Rock Creek Pharmaceuticals, Inc.
Normal and Mild Hypercholesterolemic Subjects
Long-term Effectiveness Study on Cholesterol-reducing Activity
The purpose of this study is to investigate the effect of consumption of a drinkable low fat fermented milk enriched with 0,8g or 1,6g of plant sterols on reducing plasma cholesterol (LDL-cholesterol) concentration during 12…
- Trial name
- NCT01521169
- Testing
- 1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols)., 2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols)., 3 - low-fat dairy fermented product (drinkable) without plant sterols.
- Where
- Japan
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Danone Japan
Dietary Carcinogenesis
Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100"
The primary purpose of the study is to evaluate the effectiveness of a naturally occurring clay substance (ACCS100) in reducing harmful effects of aflatoxin exposure (a carcinogen) and fumonisin (a cancer promoter).
- Trial name
- RDMEACCS100 (NCT01677195)
- Testing
- ACCS100
- Where
- United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Texas Enterosorbents Incorporated
Dietary Deficiency, Sodium
Cross-sectional, Non-randomized Observational Study to Assess the Frequency of Reduced Sodium Intake in the Primary Care Setting - LAXAP
This study is a cross-sectional epidemiological, observational study. It would be carried out in primary health care sites. The purpose of this study is estimating the percentage of patients aged 60 years or older who suffer from…
- Trial name
- LAXAP (NCT06121583)
- Where
- 14 sites in Spain
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- Casen Recordati S.L.
Obesity
Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body Weight
Compare percent change in loss of body weight between the OPTIFAST program and a food-based energy-deficit program
- Trial name
- Opti-WIN (NCT02635698)
- Testing
- Optifast, Food-Based
- Where
- 9 sites in United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Obesity and Type 2 Diabetes
Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2…
- Trial name
- RESOLVE-1 (NCT07055516)
- Testing
- NT-0796
- Where
- 11 sites in United States
- Volunteers
- 176 people
- Sponsor
- Rezera (formerly NodThera Limited)
Obesity
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
- Trial name
- RESOLVE-2 (NCT07220629)
- Testing
- NT-0796
- Where
- 9 sites in United States
- Volunteers
- 82 people
- Sponsor
- Rezera (formerly NodThera Limited)
Weight Management, Diet Conditions
A to Z Study Follow-up: Collection of DNA Data From Buccal Swabs
The goal of this study is to determine the association between genotypes and diet. The weight and weight loss data are already available from the previously completed study called: A to Z Study - Benefits and Risks of Alternative…
- Conditions
- Weight Management, Diet Conditions, Dietary Recommendations, Overweight Management
- Trial name
- NCT00866151
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Interleukin Genetics, Inc.
Hypertension
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
This study will compare the effects of high and low level sodium (salt) diets on blood pressure in patients with hypertension (high blood pressure) who are taking aliskiren 300 mg.
- Trial name
- NCT00441064
- Testing
- Aliskiren
- Where
- 19 sites in United States
- Volunteers
- 132 people
- Sponsor
- Novartis
Mild Cognitive Impairment, Metabolic Syndrome
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts…
- Trial name
- NCT03319173
- Testing
- Dietary intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Secondary Hyperoxaluria, Nephrolithiasis
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
Evaluate the safety, tolerability, and efficacy of 28 days of treatment with ALLN-177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and kidney stones.
- Conditions
- Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria, Kidney Stones
- Trial name
- NCT02547805
- Testing
- ALLN-177
- Where
- 22 sites in United States
- Volunteers
- 66 people
- Sponsor
- Allena Pharmaceuticals
Endometriosis
Pilot Study on a Dietary Supplement With EndoGen™ as Adjunct Therapy in Women With Endometriosis
Current treatments for endometriosis, such as NSAIDs and hormone therapies, are meant for long-term use but often cause side effects, including stomach, liver, heart, and kidney issues; allergies; and hormonal problems like…
- Trial name
- NCT07228975
- Testing
- MetrioFen Gocce
- Where
- 7 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Endok s.r.l.
Blood Pressure, HDL Low
Effects of a 10 Component Dietary Supplement on Health and the Quality of Life
This open-label field trial evaluates the effects of treatment with a multi-pathway dietary supplement (Stem Cell 100+) that has been commercially available for several years.
- Conditions
- Blood Pressure, HDL Low, Stress, Lung Function Decreased
- Trial name
- NCT03052491
- Testing
- Stem Cell 100+
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Centagen, Inc.
Obesity
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
To evaluate the weight loss effect and safety of 400 mg velneperit and 120 mg orlistat administered individually or combined three times per day for 24 weeks while on a reduced calorie diet (RCD) and also to evaluate the…
- Trial name
- NCT01126970
- Testing
- Velneperit 400 mg, Orlistat 120 mg, Reduced Calorie Diet
- Where
- 25 sites in United States
- Volunteers
- 486 people
- Sponsor
- Shionogi
Secondary Hyperoxaluria, Nephrolithiasis
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones
The purpose of this study is to evaluate the safety, tolerability, and efficacy of different doses of ALLN 177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and recurrent kidney stones.
- Conditions
- Secondary Hyperoxaluria, Nephrolithiasis, Kidney Stones, Hyperoxaluria
- Trial name
- NCT02503345
- Testing
- ALLN-177 low dose, ALLN-177 mid dose, ALLN-177 high dose
- Where
- 16 sites in United States
- Volunteers
- 32 people
- Sponsor
- Allena Pharmaceuticals